Why Stage 3 Breast Cancer Doesn’t Always Mean Immediate Surgery
“Shouldn’t it be removed as soon as possible — even a day sooner?” This reaction is common among patients and their families following a cancer...
Search results for "hormone receptor"
Hanmi’s ‘Epe’ Wins MFDS Approval, Becoming South Korea’s First Homegrown GLP-1 Obesity Drug
A domestically developed therapy has entered South Korea’s obesity treatment market, long dominated by imported products such as Wegovy and Mounjaro.
How High Blood Pressure Accelerates Joint Wear in Older Adults: A 'Brain Hormone' May Be to Blame
October 2 marks "Senior Citizens' Day" in South Korea—a statutory observance intended to foster respect for older...
Endocrinologist Woo Chang-yoon Touts ‘Natural Wegovy’ Egg and Olive Oil Combo to Tame Cravings
Woo Chang-yoon, an endocrinologist who has emerged as a prominent voice behind the “natural Wegovy” diet trend, has...
Does Wegovy Triple Depression Risk? Real-World Data from Korean Hospitals Yields Nuanced Findings
A recent observational study indicates that individuals taking popular GLP-1 receptor agonist obesity medications may...
Can Eggs and Olive Oil Help You Lose Weight? Why the "Natural Wegovy" Trend Can Backfire
A viral diet trend touting olive oil drizzled over boiled eggs as a "natural Wegovy" has gained traction among...
Hanmi Licenses Muscle-Preserving Obesity Drug Candidate to Genentech in $2.3 Billion Deal
Hanmi Pharmaceutical has entered into an exclusive global licensing agreement with Genentech, a member of the Roche...
'Natural Wegovy' Is a Myth, Surgeon Warns, Pushing Back on Viral Diet Trend
A viral social media trend promoting a "Natural Wegovy" diet—eating boiled eggs drizzled with olive oil—has prompted a...
Why Pancreatic Cancer Is Less Common in Women: Childbirth History May Offer Clues
Pancreatic cancer is notoriously difficult to attribute to a single cause. However, a major South Korean study tracking...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.